Mitoxantrone Pharmacokinetics

  • E. Schleyer
  • A. Kamischke
  • C. C. Kaufmann
  • M. Unterhalt
  • W. Hiddemann
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)


Mitoxantrone is the first fully synthesized anthrachinone derivative (1,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino] ethyl] amino]-9, 10-anthracenedione dihydrochloride, NSC 301,739), which was introduced into cancer therapy in the late 1970s. Since then it has been widely used for the treatment of advanced breast cancer, acute leukemia, malignant lymphomas, and hepatocellular carcinoma [11,12]. In spite of its extensive clinical application knowledge about the pharmacokinetic characteristics of Mitoxantrone including key parameters as the terminal elimination half-life and especially its main metabolism and excretion are still not fully elucidated. Hence, substantial differences in the values for the terminal elimination half-life emerge from a comparative analysis of previously published reports ranging from 3 to 215 h. Even less information is available about the pharmacokinetics of the mono- and dicarboxyacid derivatives of Mitoxantrone which are considered as its main metabolites. Data on the potential impact of these substances, which have no cytotoxic activity, on the kinetic of the parent compound are almost exclusively derived from animal models and not entirely investigated [1, 3, 4, 5, 6, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 21, 22, 24, 25, 26, 28, 29, 30, 31]. In addition new metabolites of Mitoxantrone were recently identified in pleura fluid by our group and were characterized in more detail by Blanz et al. [6, 27]. These data strongly suggest that the degree of Mitoxantrone metabolism has been underestimated in previous investigations and that special attention must be directed to enravell the kinetic behaviour of the parent drug and its main metabolites.


Acute Leukemia Renal Elimination Main Metabolite Total Body Clearance Terminal Elimination Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alberts OS, Peng YM, Leigh S, Davis TP, Woodward DL (1983) Disposition of Mitoxantrone in cancer patients. Cancer Treatment Reviews 10 (B) 23–27PubMedCrossRefGoogle Scholar
  2. 2.
    Alberts OS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of Mitoxantrone: mode of action and pharmacokinetics. Investigational New Drugs, 3, 101–107PubMedGoogle Scholar
  3. 3.
    Avramis V (1982) Pharmacokinetics of dihydroxyanthracenedione (DHAD) and its metabolites in rats. Abstract. Pharmacologist. 24, 241Google Scholar
  4. 4.
    Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A (1986) Pharmacokinetics of Mitoxantrone in man and laboratory animals. Drug Metabolism Reviews, 17, 311–329PubMedCrossRefGoogle Scholar
  5. 5.
    Blanz J, Mewes K, Ehninger G, Proksch B, Greger B, Waidelich O, Zeller KP (1991) Isolation and structure elucidation of urinary metabolites of Mitoxantrone. Cancer Research, 51, 3427–3433PubMedGoogle Scholar
  6. 6.
    Blanz J, Mewes K, Ehninger G, Proksch B, Waidelich O, Greger B, Zeller KP (1991) Evidence for oxidative activation of Mitoxantrone in human, pig and rat. Drug Metabolism and Disposition, 19, Nr. 5, 871–880PubMedGoogle Scholar
  7. 7.
    Chiccarelli FS, Morrison JA, Gautam SR (1984) Biliary pharmacokinetics of Mitoxantrone in rat following different intravenous doses and characteristics of drug related material in bile. Abstract Federal Proceedings, 43, 345Google Scholar
  8. 8.
    Chiccarelli FS, Morrison JA, Cosulich DB, Perkinson NA, Ridge ON (1986) Identification of human urinary Mitoxantrone metabolites. Cancer Research, 46, 4858–4861PubMedGoogle Scholar
  9. 9.
    Ehninger G, Proksch B, Schiller E (1985) Detection and separation of Mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography. Journal of Chromatography, Biomedical Applications, 342, 119–127CrossRefGoogle Scholar
  10. 10.
    Ehninger G, Proksch B, Heinzel G, Woodward DL (1986) Clinical pharmacology of mitoxantrone. Cancer Treat Rep 70, 1373–1378PubMedGoogle Scholar
  11. 11.
    Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of Mitoxantrone, a review. Clin. Pharmacokinet. 18, Nr 5, 365–380PubMedCrossRefGoogle Scholar
  12. 12.
    Faulds O, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone: A review of its pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 41, Nr 3, 400–449PubMedCrossRefGoogle Scholar
  13. 13.
    Forni M, Lachau S, Huguet F, Canal P, Laurent G, Chevreau C, Roche H, Bugat R (1991) Phase I/II pharmacokinetic study of Mitoxantrone by continuous venous infusion in patients with solid tumors and Iymphoproliferative diseases. Eur J Cancer 27, Nr 6. 735–739PubMedCrossRefGoogle Scholar
  14. 14.
    Greidanus J, De Vries EGE, Mulder NH, Sleijfer DT, Uges ORA, Oosterhuis B, Willemse PHB (1989) A phase I pharmacokinetic study of 21 day continuous infusion Mitoxantrone. Journal of Clinical Oncology, 7, Nr 6, 790–797PubMedGoogle Scholar
  15. 15.
    Heinzel G, in Bozler G, Van Rossum JM (Ed) (1982) Pharmacokinetics during drug development: Data analysis and evaluation techniques. Gustav Fischer Verlag, Stuttgart, New York, 207–211Google Scholar
  16. 16.
    Hu OYP, Chang SP, Law CK, Jian JM, Chen KY (1992) Pharmacokinetic and pharmacodynamics studies with Mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer, 69, Nr 4, 847–853PubMedCrossRefGoogle Scholar
  17. 17.
    Larsen RA, Daly KM, Choi KE, Han OS, Sinkule JA (1987) A clinical and pharmacokinetic study of Mitoxantrone in acute nonlymphocytic leukemia. Journal of Clin Oncol 5, Nr 3, 391–397Google Scholar
  18. 18.
    Linkesch W, Thaler J, Gattringer C, Kowalinka G (1990) Continuous Infusion of Mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia. Haematol. Bluttransfus. 33, 330–332Google Scholar
  19. 19.
    Lu K, Savaraj N, Loo L T (1984) Pharmacological disposition of 1,4-dihydroxy-5-8-bis{[2-[(2-hydroxyethyl) amino] ethyl] amino}-9-10-anthracenedione dihydrochloride in the dog. Cancer Chemotherapy and Pharmacology, 13, 64–66CrossRefGoogle Scholar
  20. 20.
    McPherson JS, Smyth JF, Clements JA, Ramsay MW, Warrington PS et al. (1984) Pharmacokinetics and metabolism of Mitoxantrone. British Journal of Cancer, 50, 252–253Google Scholar
  21. 21.
    Malspeis L, Neidhart JA (1983) Pharmacokinetics of Novantrone. Clin dokumentation, LederleGoogle Scholar
  22. 22.
    Michaux J, Hulhoven R, Detry J (1983) Pharmacokinetics of Mitoxantrone HCL following administration of a single intravenous dose in patients with acute myelogenous leukemia. Clin Res Int 3, Nr. 42Google Scholar
  23. 23.
    Muus P, Linssen P, Knops R, Wessels H, De Witte T (1992) Mitoxantrone: Pharmacokinetic and pharmacodynamic Studies in patients with leukemia. Haematology and Blood Transfusion, 34, Acute Leukemias - Pharmacokinetics, 300–303Google Scholar
  24. 24.
    Ogawa M, Sampi K, Tsukui T, Oguru M, Sakai K (1986) Pharmacokinetic study of Mitoxantrone. Jpn J Cancer Chemotherapy, 13, Nr 10, 3028–3033Google Scholar
  25. 25.
    Rowland CG, Sewell G (1987) Optimal drug delivery: A phase II study of continuously infused Mitoxantrone. 4th ECO, 117Google Scholar
  26. 26.
    Savaraj N, Lu K, Manuel V, Loo LT (1982) Pharmacology of Mitoxantrone in cancer patients. Cancer Chemotherapy and Pharmacology 8: 113–117PubMedCrossRefGoogle Scholar
  27. 27.
    Schleyer E, Schneider F, Kaufmann CC, Unterhalt M, Hiddemann W (1990) Pharmacokinetics of Mitoxantrone in plasma and pleura fluid. Blut 61, 138Google Scholar
  28. 28.
    Smyth JF, MacPherson JS, Warrington PS, Leonard RCF, Wolf CR (1986) The clinical pharmacology of Mitoxantrone. Cancer Chemotherapy and Pharmacology, 17, 149–152PubMedCrossRefGoogle Scholar
  29. 29.
    Stewart JA, McCormack JJ, Krakoff IH (1982) Clinical and clinical pharmacologic studies of Mitoxantrone. Cancer Treat Rep 66, 1327–1331PubMedGoogle Scholar
  30. 30.
    Van Belle SJP, De Planque MM, Smith IE, Van Oosterom AT, Schoemaker TJ, Deneve W, McVie JG (1986) Pharmacokinetics of Mitoxantrone in humans following single agent infusion or intra-arterial injection therapy or combinedagent infusion therapy. Cancer Chemotherapy and Pharmacology, 18, 27–32PubMedCrossRefGoogle Scholar
  31. 31.
    Wolf CR, MacPherson JS, Smyth JF (1986) Evidence for the metabolism of Mitoxantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronyl transferases. Biochemical Pharmacology 35, 1577–1581PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • E. Schleyer
    • 1
  • A. Kamischke
    • 1
  • C. C. Kaufmann
    • 1
  • M. Unterhalt
    • 1
  • W. Hiddemann
    • 1
  1. 1.Department of Internal Medicine, Division of Hematology/OncologyUniversity of GöttingenGöttingenGermany

Personalised recommendations